The Menactra Vaccine is utilized to prevent meningococcal disease, actively immunizing individuals against invasive Neisseria meningitidis serogroups A, C, Y, and W-135. Approved for those aged 9 months through 55 years, it should be administered by a healthcare professional and not self-administered. It is crucial to complete all vaccine doses for effectiveness. Individuals aged 15 to 55 at continued risk may receive a single booster dose after 4 to 6 years since the prior dose, with caution against intravenous, subcutaneous, or intradermal administration.